Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Time to Buy? CV Sciences Shows 85% Year-Over-Year Sales Growth

Time to Buy? CV Sciences Shows 85% Year-Over-Year Sales GrowthCV Sciences, Inc. (OTCQB: CVSI) recently announced the company’s financial results for the first quarter of 2019 which ended on March 31st, 2019. It was revealed in its Q1 2019 results that the company has a new record from an 85% increase in year-over-year sales revenue.

The company managed to increase its retail footprint by over 1,000 stores in the last year to a total of 3,308 stores, which represents a 48% increase from the total of stores reported on December 31st, 2018. CV Sciences also managed to increase its cash balance to $13.6 million from an operations gain of $0.8 million in cash.

CVSI has been on a tear and, as of March, the stock was up over 1000% in the last year.

Joseph Dowling, Chief Executive Officer of CV Sciences, stated: “We continued to expand retail distribution of the PlusCBD Oil™ brand and drive sales growth during the first quarter. We generated 85% revenue growth over prior year, achieving another record quarter, with strong gross margin performance.

{{cta(’69f63bd3-e695-415f-8c83-b207c29317a6′)}}

The PlusCBD Oil™ brand is now available in over 3,300 stores nationwide, including national food, drug and mass merchandiser accounts. As anticipated, since the passage of the 2018 Farm Bill, we have seen significant interest in the hemp-derived CBD category across retailers and channels, and we are in discussions with multiple retailers for new retail placements. We are making the investments across the organization to position ourselves to capitalize on the growing retailer and consumer demand.

The company’s trademarked cannabidiol (CBD) product, PlusCBD Oil™, gained significant traction in the CBD market. SPINS, the leader in syndicated data and insights for natural products, recognizes PlusCBD Oil™ as the top-selling hemp-derived CBD product available on the market.

Curious about how you can make money investing in cannabis? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.

Source

Time to Buy? CV Sciences Shows 85% Year-Over-Year Sales Growth

About Cannin: Your Marijuana Stock Experts

Cannin is your #1 trusted resource for marijuana and hemp stock investment opportunities. Our global team of experts evaluates all emerging marijuana and hemp stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana and hemp stock investments for 2020. 

Use Cannin as your resource for:

Is it too late to invest in marijuana or hemp stocks? No! This is the perfect time to invest.

Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana and hemp stocks is now. Are you looking to buy stock in hemp companies or marijuana companies for 2020? Interested in emerging penny hemp stock companies? Looking for the best Canadian marijuana stocks to invest in? We can help.

Predict price movements of marijuana and hemp stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +25% Gains in 2020
  • +49.8% Gains in 2019
  • Backtested since 2012

We’re so confident you’ll love our signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best marijuana stocks – we’ll show you how at cannin.com

Can we start writing exclusively about Hemp-Only companies? These include the following: Charlotte’s Web, GW Pharma, CV Sciences, Canopy Growth, Elixinol, Organigram, GrowLife, Emerald Health, Neptune, Global Hemp Group. Also, please see the attached report with additional hemp only companies with analysis. It’s from last year so the data is not current but worth a look.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks to Buy

Time to Buy? CV Sciences Shows 85% Year-Over-Year Sales Growth